EQRx Interviews: Drug Pricing Approach, SPACs, and Controversy

EQRx is raising billions of dollars, and an even bigger debate, with an ambitious drug-pricing plan. The biotech plans to price drugs 50% to 70% below competition — a radical approach in the industry. While EQRx is closing a massive SPAC deal to go public, skeptics question its strategy and hype. The leaders of EQRx are intent on hammering a single word into people’s minds: scale.

Read the source article at Business
2021-08-23 05:36:00